What is the current valuation of the Radiopharmaceutical Theranostics Market as of 2024?

The market valuation was 2.11 USD Billion in 2024. Read More

What is the projected market size for the Radiopharmaceutical Theranostics Market by 2035?

The projected valuation for 2035 is 4.374 USD Billion. Read More

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR during this period is 6.85%. Read More

Which application segments are driving growth in the Radiopharmaceutical Theranostics Market?

Key application segments include Oncology, Cardiology, Neurology, and Endocrinology, with Oncology valued at 1.95 USD Billion by 2035. Read More

What are the leading radioisotopes used in the market?

Fluorine-18 (18F) and Gallium-68 (68Ga) are prominent, with 18F projected to reach 1.75 USD Billion by 2035. Read More

How do the modalities of imaging impact the Radiopharmaceutical Theranostics Market?

PET and SPECT modalities are crucial, with PET expected to grow to 1.75 USD Billion by 2035. Read More

Who are the key players in the Radiopharmaceutical Theranostics Market?

Notable players include Novartis, Bayer, GE Healthcare, and Siemens Healthineers. Read More

What target diseases are primarily addressed by the market?

The market focuses on Cancer, Cardiovascular Disease, Neurological Disorders, and Endocrine Disorders, with Cancer projected to reach 2.0 USD Billion by 2035. Read More

How does the market compare across different regions?

While specific regional data is not provided, the overall growth trajectory suggests increasing investments in North America and Europe. Read More

What trends are influencing the future of the Radiopharmaceutical Theranostics Market?

Trends include advancements in imaging technologies and increasing demand for personalized medicine, likely enhancing market growth. Read More

Radiopharmaceutical Theranostics Market

ID: MRFR/HC/25439-HCR

128 Pages

Rahul Gotadki

Last Updated: April 08, 2026

Radiopharmaceutical Theranostics Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Endocrinology), By Radioisotope (Fluorine-18 (18F), Carbon-11 (11C), Nitrogen-13 (13N), Gallium-68 (68Ga), By Modality (PET (Positron Emission Tomography), SPECT (Single-Photon Emission Computed Tomography), SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography), PET/CT (Positron Emission Tomography/Computed Tomography), By Target Disease (Cancer, Cardiovascular Disease, Neurological Disorders, Endocrine Disorders) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Radiopharmaceutical Theranostics Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.85%

2024 Market Size$ 2.11 Billion

2025 Market Size$ 2.26 Billion

2035 Market Size$ 4.37 Billion

Key Players

Companies such as Novartis

Bayer

GE Healthcare

Siemens Healthineers

Lantheus Medical Imaging

Bracco Imaging

Trends

Integration of Diagnostics and Therapeutics
Regulatory Support and Innovation
Collaboration in Research and Development

Opportunities

Rising Incidence of Cancer
Supportive Regulatory Frameworks
Growing Demand for Personalized Medicine

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Application (USD Billion) | |
  1. 4.1.1 Oncology | |
  2. 4.1.2 Cardiology | |
  3. 4.1.3 Neurology | |
  4. 4.1.4 Endocrinology |
2. 4.2 Healthcare, BY Radioisotope (USD Billion) | |
  1. 4.2.1 Fluorine-18 (18F) | |
  2. 4.2.2 Carbon-11 (11C) | |
  3. 4.2.3 Nitrogen-13 (13N) | |
  4. 4.2.4 Gallium-68 (68Ga) |
3. 4.3 Healthcare, BY Modality (USD Billion) | |
  1. 4.3.1 PET (Positron Emission Tomography) | |
  2. 4.3.2 SPECT (Single-Photon Emission Computed Tomography) | |
  3. 4.3.3 SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography) | |
  4. 4.3.4 PET/CT (Positron Emission Tomography/Computed Tomography) |
4. 4.4 Healthcare, BY Target Disease (USD Billion) | |
  1. 4.4.1 Cancer | |
  2. 4.4.2 Cardiovascular Disease | |
  3. 4.4.3 Neurological Disorders | |
  4. 4.4.4 Endocrine Disorders |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Novartis (CH) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bayer (DE) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 GE Healthcare (GB) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Siemens Healthineers (DE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Lantheus Medical Imaging (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Bracco Imaging (IT) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Elekta (SE) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Telix Pharmaceuticals (AU) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Iradimed Corporation (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY APPLICATION |
7. 6.4 US MARKET ANALYSIS BY RADIOISOTOPE |
8. 6.5 US MARKET ANALYSIS BY MODALITY |
9. 6.6 US MARKET ANALYSIS BY TARGET DISEASE |
10. 6.7 CANADA MARKET ANALYSIS BY APPLICATION |
11. 6.8 CANADA MARKET ANALYSIS BY RADIOISOTOPE |
12. 6.9 CANADA MARKET ANALYSIS BY MODALITY |
13. 6.10 CANADA MARKET ANALYSIS BY TARGET DISEASE |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION |
16. 6.13 GERMANY MARKET ANALYSIS BY RADIOISOTOPE |
17. 6.14 GERMANY MARKET ANALYSIS BY MODALITY |
18. 6.15 GERMANY MARKET ANALYSIS BY TARGET DISEASE |
19. 6.16 UK MARKET ANALYSIS BY APPLICATION |
20. 6.17 UK MARKET ANALYSIS BY RADIOISOTOPE |
21. 6.18 UK MARKET ANALYSIS BY MODALITY |
22. 6.19 UK MARKET ANALYSIS BY TARGET DISEASE |
23. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION |
24. 6.21 FRANCE MARKET ANALYSIS BY RADIOISOTOPE |
25. 6.22 FRANCE MARKET ANALYSIS BY MODALITY |
26. 6.23 FRANCE MARKET ANALYSIS BY TARGET DISEASE |
27. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION |
28. 6.25 RUSSIA MARKET ANALYSIS BY RADIOISOTOPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY MODALITY |
30. 6.27 RUSSIA MARKET ANALYSIS BY TARGET DISEASE |
31. 6.28 ITALY MARKET ANALYSIS BY APPLICATION |
32. 6.29 ITALY MARKET ANALYSIS BY RADIOISOTOPE |
33. 6.30 ITALY MARKET ANALYSIS BY MODALITY |
34. 6.31 ITALY MARKET ANALYSIS BY TARGET DISEASE |
35. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION |
36. 6.33 SPAIN MARKET ANALYSIS BY RADIOISOTOPE |
37. 6.34 SPAIN MARKET ANALYSIS BY MODALITY |
38. 6.35 SPAIN MARKET ANALYSIS BY TARGET DISEASE |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY RADIOISOTOPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY MODALITY |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY TARGET DISEASE |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY APPLICATION |
45. 6.42 CHINA MARKET ANALYSIS BY RADIOISOTOPE |
46. 6.43 CHINA MARKET ANALYSIS BY MODALITY |
47. 6.44 CHINA MARKET ANALYSIS BY TARGET DISEASE |
48. 6.45 INDIA MARKET ANALYSIS BY APPLICATION |
49. 6.46 INDIA MARKET ANALYSIS BY RADIOISOTOPE |
50. 6.47 INDIA MARKET ANALYSIS BY MODALITY |
51. 6.48 INDIA MARKET ANALYSIS BY TARGET DISEASE |
52. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION |
53. 6.50 JAPAN MARKET ANALYSIS BY RADIOISOTOPE |
54. 6.51 JAPAN MARKET ANALYSIS BY MODALITY |
55. 6.52 JAPAN MARKET ANALYSIS BY TARGET DISEASE |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY RADIOISOTOPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY MODALITY |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY TARGET DISEASE |
60. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION |
61. 6.58 MALAYSIA MARKET ANALYSIS BY RADIOISOTOPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY MODALITY |
63. 6.60 MALAYSIA MARKET ANALYSIS BY TARGET DISEASE |
64. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION |
65. 6.62 THAILAND MARKET ANALYSIS BY RADIOISOTOPE |
66. 6.63 THAILAND MARKET ANALYSIS BY MODALITY |
67. 6.64 THAILAND MARKET ANALYSIS BY TARGET DISEASE |
68. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION |
69. 6.66 INDONESIA MARKET ANALYSIS BY RADIOISOTOPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY MODALITY |
71. 6.68 INDONESIA MARKET ANALYSIS BY TARGET DISEASE |
72. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION |
73. 6.70 REST OF APAC MARKET ANALYSIS BY RADIOISOTOPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY MODALITY |
75. 6.72 REST OF APAC MARKET ANALYSIS BY TARGET DISEASE |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION |
78. 6.75 BRAZIL MARKET ANALYSIS BY RADIOISOTOPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY MODALITY |
80. 6.77 BRAZIL MARKET ANALYSIS BY TARGET DISEASE |
81. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION |
82. 6.79 MEXICO MARKET ANALYSIS BY RADIOISOTOPE |
83. 6.80 MEXICO MARKET ANALYSIS BY MODALITY |
84. 6.81 MEXICO MARKET ANALYSIS BY TARGET DISEASE |
85. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION |
86. 6.83 ARGENTINA MARKET ANALYSIS BY RADIOISOTOPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY MODALITY |
88. 6.85 ARGENTINA MARKET ANALYSIS BY TARGET DISEASE |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY RADIOISOTOPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODALITY |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET DISEASE |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY RADIOISOTOPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY MODALITY |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TARGET DISEASE |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY RADIOISOTOPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY MODALITY |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TARGET DISEASE |
102. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION |
103. 6.100 REST OF MEA MARKET ANALYSIS BY RADIOISOTOPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY MODALITY |
105. 6.102 REST OF MEA MARKET ANALYSIS BY TARGET DISEASE |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY RADIOISOTOPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY RADIOISOTOPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY MODALITY, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY MODALITY, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY RADIOISOTOPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY MODALITY, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY TARGET DISEASE, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Radiopharmaceutical Theranostics Market Segmentation

Radiopharmaceutical Theranostics Market By Application (USD Billion, 2025-2035)

Oncology
Cardiology
Neurology
Endocrinology

Radiopharmaceutical Theranostics Market By Radioisotope (USD Billion, 2025-2035)

Fluorine-18 (18F)
Carbon-11 (11C)
Nitrogen-13 (13N)
Gallium-68 (68Ga)

Radiopharmaceutical Theranostics Market By Modality (USD Billion, 2025-2035)

PET (Positron Emission Tomography)
SPECT (Single-Photon Emission Computed Tomography)
SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography)
PET/CT (Positron Emission Tomography/Computed Tomography)

Radiopharmaceutical Theranostics Market By Target Disease (USD Billion, 2025-2035)

Cancer
Cardiovascular Disease
Neurological Disorders
Endocrine Disorders

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”